Is HYPD or EQ more profitable?

Equillium's return on equity of -61.43% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Equillium N/A -61.43% -53.72%

Do analysts rate HYPD or CNTN?

Hyperion DeFi presently has a consensus price target of $6.95, indicating a potential upside of 176.89%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Hyperion DeFi is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperion DeFi 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HYPD or CNTN more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Hillstream Biopharma N/A -31.50% -24.72%

Hyperion DeFi (HYPD) Competitors

$2.51 -0.13 (-4.92%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.51 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

HYPD vs. PRQR, EQ, TNXP, CNTN, and ACOG

Should you buy Hyperion DeFi stock or one of its competitors? MarketBeat compares Hyperion DeFi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperion DeFi include ProQR Therapeutics (PRQR), Equillium (EQ), Tonix Pharmaceuticals (TNXP), Hillstream Biopharma (CNTN), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

How does Hyperion DeFi compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

ProQR Therapeutics currently has a consensus price target of $7.33, indicating a potential upside of 326.36%. Hyperion DeFi has a consensus price target of $6.95, indicating a potential upside of 176.89%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, ProQR Therapeutics had 3 more articles in the media than Hyperion DeFi. MarketBeat recorded 4 mentions for ProQR Therapeutics and 1 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.93 beat ProQR Therapeutics' score of 0.55 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
ProQR Therapeutics	Positive
Hyperion DeFi	Positive

Hyperion DeFi has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Hyperion DeFi	N/A	-91.59%	-73.08%

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ProQR Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.49, meaning that its share price is 149% more volatile than the broader market.

Hyperion DeFi has lower revenue, but higher earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$13.42M	13.50	-$47.73M	-$0.50	N/A
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A

Summary

ProQR Therapeutics beats Hyperion DeFi on 10 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Equillium?

Hyperion DeFi (NASDAQ:HYPD) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Equillium has lower revenue, but higher earnings than Hyperion DeFi. Equillium is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A
Equillium	N/A	N/A	-$22.40M	-$0.32	N/A

Hyperion DeFi presently has a consensus target price of $6.95, indicating a potential upside of 176.89%. Equillium has a consensus target price of $7.57, indicating a potential upside of 204.07%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.82

Hyperion DeFi has a beta of 2.49, meaning that its share price is 149% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, Equillium had 5 more articles in the media than Hyperion DeFi. MarketBeat recorded 6 mentions for Equillium and 1 mentions for Hyperion DeFi. Equillium's average media sentiment score of 1.34 beat Hyperion DeFi's score of 0.93 indicating that Equillium is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Equillium	Positive

Equillium's return on equity of -61.43% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Equillium	N/A	-61.43%	-53.72%

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 27.0% of Equillium shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Equillium beats Hyperion DeFi on 12 of the 15 factors compared between the two stocks.

How does Hyperion DeFi compare to Tonix Pharmaceuticals?

Hyperion DeFi (NASDAQ:HYPD) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for Hyperion DeFi. Tonix Pharmaceuticals' average media sentiment score of 0.94 beat Hyperion DeFi's score of 0.93 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Tonix Pharmaceuticals	Positive

Hyperion DeFi has a beta of 2.49, indicating that its stock price is 149% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Hyperion DeFi has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Hyperion DeFi currently has a consensus target price of $6.95, indicating a potential upside of 176.89%. Tonix Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 142.91%. Given Hyperion DeFi's higher possible upside, equities analysts clearly believe Hyperion DeFi is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Hyperion DeFi has higher earnings, but lower revenue than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A
Tonix Pharmaceuticals	$13.11M	12.01	-$124.02M	-$14.36	N/A

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Hyperion DeFi beats Tonix Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Hyperion DeFi compare to Hillstream Biopharma?

Hyperion DeFi (NASDAQ:HYPD) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Hillstream Biopharma has lower revenue, but higher earnings than Hyperion DeFi. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Hillstream Biopharma had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 2 mentions for Hillstream Biopharma and 1 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.93 beat Hillstream Biopharma's score of 0.62 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Hillstream Biopharma	Positive

Hyperion DeFi presently has a consensus price target of $6.95, indicating a potential upside of 176.89%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Hyperion DeFi is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hyperion DeFi has a beta of 2.49, indicating that its stock price is 149% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Hillstream Biopharma's return on equity of -31.50% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Summary

Hyperion DeFi beats Hillstream Biopharma on 9 of the 14 factors compared between the two stocks.

How does Hyperion DeFi compare to Alpha Cognition?

Hyperion DeFi (NASDAQ:HYPD) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Hyperion DeFi has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Alpha Cognition	-232.23%	-58.35%	-45.99%

Hyperion DeFi presently has a consensus target price of $6.95, suggesting a potential upside of 176.89%. Alpha Cognition has a consensus target price of $16.00, suggesting a potential upside of 102.53%. Given Hyperion DeFi's higher probable upside, equities research analysts plainly believe Hyperion DeFi is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

25.8% of Hyperion DeFi shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hyperion DeFi has a beta of 2.49, suggesting that its stock price is 149% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market.

Alpha Cognition has higher revenue and earnings than Hyperion DeFi. Alpha Cognition is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A
Alpha Cognition	$10.83M	15.89	-$20.67M	-$1.35	N/A

In the previous week, Alpha Cognition had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 2 mentions for Alpha Cognition and 1 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.93 beat Alpha Cognition's score of 0.43 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Alpha Cognition	Neutral

Summary

Alpha Cognition beats Hyperion DeFi on 9 of the 16 factors compared between the two stocks.

Get Hyperion DeFi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPD vs. The Competition

Export

Metric	Hyperion DeFi	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.02M	$434.82M	$6.87B	$12.26B
Dividend Yield	N/A	3.90%	2.67%	9.79%
P/E Ratio	-0.25	3.16	27.11	23.64
Price / Sales	36.48	6,592.20	512.89	89.27
Price / Cash	N/A	13.13	50.54	59.64
Price / Book	0.53	83.70	10.28	6.07
Net Income	-$45.31M	-$96.07M	$3.60B	$331.99M
7 Day Performance	-8.39%	-0.66%	-1.27%	-0.63%
1 Month Performance	-15.20%	-1.07%	-0.37%	-2.00%
1 Year Performance	-67.40%	56.07%	18.30%	13.62%

Hyperion DeFi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPD Hyperion DeFi	3.1705 of 5 stars	$2.51 -4.9%	$6.95 +176.9%	-69.3%	$40.02M	$1.04M	N/A	40
PRQR ProQR Therapeutics	3.8698 of 5 stars	$1.71 +0.3%	$7.33 +330.1%	-23.9%	$180.59M	$17.99M	N/A	180	Positive News Short Interest Increase
EQ Equillium	3.1577 of 5 stars	$2.84 -1.4%	$7.57 +166.7%	+578.5%	$179.57M	$41.10M	N/A	40	News Coverage Positive News Analyst Upgrade
TNXP Tonix Pharmaceuticals	3.9658 of 5 stars	$11.06 -5.5%	$24.00 +117.1%	-77.9%	$176.95M	$13.11M	N/A	50
CNTN Hillstream Biopharma	0.2274 of 5 stars	$2.30 +1.1%	N/A	N/A	$176.53M	N/A	N/A	2	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPD) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperion DeFi (HYPD) Competitors

HYPD vs. PRQR, EQ, TNXP, CNTN, and ACOG

How does Hyperion DeFi compare to ProQR Therapeutics?

Summary

How does Hyperion DeFi compare to Equillium?

Summary

How does Hyperion DeFi compare to Tonix Pharmaceuticals?

Summary

How does Hyperion DeFi compare to Hillstream Biopharma?

Summary

How does Hyperion DeFi compare to Alpha Cognition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperion DeFi (HYPD) Competitors

HYPD vs. PRQR, EQ, TNXP, CNTN, and ACOG

How does Hyperion DeFi compare to ProQR Therapeutics?

Do analysts prefer PRQR or HYPD?

Does the media favor PRQR or HYPD?

Is PRQR or HYPD more profitable?

Do institutionals and insiders hold more shares of PRQR or HYPD?

Which has more volatility and risk, PRQR or HYPD?

Which has better earnings & valuation, PRQR or HYPD?

Summary

How does Hyperion DeFi compare to Equillium?

Which has preferable valuation & earnings, HYPD or EQ?

Do analysts rate HYPD or EQ?

Which has more volatility & risk, HYPD or EQ?

Does the media favor HYPD or EQ?

Is HYPD or EQ more profitable?

Do institutionals & insiders hold more shares of HYPD or EQ?

Summary

How does Hyperion DeFi compare to Tonix Pharmaceuticals?

Does the media favor HYPD or TNXP?

Which has more risk and volatility, HYPD or TNXP?

Is HYPD or TNXP more profitable?

Do analysts rate HYPD or TNXP?

Which has stronger earnings and valuation, HYPD or TNXP?

Do insiders & institutionals hold more shares of HYPD or TNXP?

Summary

How does Hyperion DeFi compare to Hillstream Biopharma?

Which has better valuation and earnings, HYPD or CNTN?

Do insiders and institutionals hold more shares of HYPD or CNTN?

Does the media refer more to HYPD or CNTN?

Do analysts rate HYPD or CNTN?

Which has more volatility and risk, HYPD or CNTN?

Is HYPD or CNTN more profitable?

Summary

How does Hyperion DeFi compare to Alpha Cognition?

Is HYPD or ACOG more profitable?

Do analysts prefer HYPD or ACOG?

Do institutionals and insiders have more ownership in HYPD or ACOG?

Which has more risk & volatility, HYPD or ACOG?

Which has higher valuation & earnings, HYPD or ACOG?

Does the media favor HYPD or ACOG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools